Unique ID issued by UMIN | UMIN000001993 |
---|---|
Receipt number | R000002430 |
Scientific Title | Effects of rosuvastatin and ezetimibe on bone turnover markers in type 2 diabetes patients with hypercholesterolemia |
Date of disclosure of the study information | 2009/05/21 |
Last modified on | 2009/06/29 03:26:43 |
Effects of rosuvastatin and ezetimibe on bone turnover markers in type 2 diabetes patients with hypercholesterolemia
Effects of rosuvastatin and ezetimibe on bone turnover markers
Effects of rosuvastatin and ezetimibe on bone turnover markers in type 2 diabetes patients with hypercholesterolemia
Effects of rosuvastatin and ezetimibe on bone turnover markers
Japan |
hypercholesterolemia with type 2 diabetes
Endocrinology and Metabolism |
Others
NO
Effects of rosuvastatin and ezetimibe on bone turnover markers
Efficacy
Bone turnover markers
Interventional
Parallel
Randomized
Open -no one is blinded
Active
2
Treatment
Medicine |
Rosuvastatin
Ezetimibe
Not applicable |
Not applicable |
Male and Female
Patients with newly diagnosed hypercholesterolemia, who visited our out clinic for education, evaluation, or treatment of type 2 diabetes, were enrolled if informed consent was obtained after a detailed explanation of the study purpose and methods.
Nobody had hepatic or renal dysfunction or nutritional derangements. All patients were free of drugs known to influence bone and calcium metabolism, such as vitamin D, bisphosphonate, or estrogen, up until the time of the study. Nobody had treatments with any cholesterol lowering agent.
40
1st name | |
Middle name | |
Last name | Ippei Kanazawa |
Shimane University School of Medicine
Internal Medicine 1
89-1 Enya-cho, Izumo, Shimane
1st name | |
Middle name | |
Last name |
Shimane University School of Medicine
Internal Medicine 1
ippei.k@med.shimane-u.ac.jp
Department of Internal Medicine 1, Shimane University School of Medicine
Department of Internal Medicine 1, Shimane University School of Medicine
Self funding
NO
2009 | Year | 05 | Month | 21 | Day |
Unpublished
Serum osteocalcin levels in the rosuvastatin group were significantly increased, while any bone marker in the ezetimibe group was not changed.
Completed
2008 | Year | 09 | Month | 01 | Day |
2008 | Year | 12 | Month | 01 | Day |
2009 | Year | 06 | Month | 01 | Day |
2009 | Year | 06 | Month | 01 | Day |
2009 | Year | 06 | Month | 01 | Day |
2009 | Year | 06 | Month | 01 | Day |
2009 | Year | 05 | Month | 21 | Day |
2009 | Year | 06 | Month | 29 | Day |
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000002430
Research Plan | |
---|---|
Registered date | File name |
Research case data specifications | |
---|---|
Registered date | File name |
Research case data | |
---|---|
Registered date | File name |